Ocular Therapeutix, Inc (OCUL) Financial Statements
Industry: Pharmaceutical Preparations
In fiscal 2025, Ocular Therapeutix reported revenue of $52.0M, down 18.5% from $63.7M the year before. Net income was -$265.9M (a -511.9% net margin), or -$1.42 per diluted share. Gross margin was 87.3% and operating margin was -519.8%. Operating activities generated -$204.9M of cash, leaving -$216.9M of free cash flow. At fiscal year end, Ocular Therapeutix held $808.1M in total assets against $153.7M in total liabilities, including $737.1M of cash and equivalents.
Open the full interactive Ocular Therapeutix financials → Quarterly statements, key ratios, valuation history and price charts.
Ocular Therapeutix Key Stats
| Share Price | $7.24 |
|---|---|
| Market Cap | $1.63B |
| Revenue YoY Growth | -18.5% |
| 52-Week Range | $6.88 – $16.11 |
| Shares Outstanding | 225.0 million (basic, 2026 Q2) |
Ocular Therapeutix Income Statement
| FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | |
|---|---|---|---|---|---|---|
| Revenue | $17.4M | $43.5M | $51.5M | $58.4M | $63.7M | $52.0M |
| Cost of Goods Sold | $2.1M | $4.4M | $4.5M | $5.3M | $5.6M | $6.6M |
| Gross Profit | $15.3M | $39.1M | $47.0M | $53.2M | $58.1M | $45.4M |
| Operating Income | -$62.8M | -$78.0M | -$78.7M | -$82.4M | -$171.8M | -$270.0M |
| Pre-Tax Income | -$155.6M | -$6.6M | -$71.0M | -$80.7M | -$193.5M | -$265.9M |
| Income Tax | $0 | $0 | $0 | $0 | $0 | $0 |
| Net Income | -$155.6M | -$6.6M | -$71.0M | -$80.7M | -$193.5M | -$265.9M |
| Diluted EPS | -$2.56 | -$0.98 | -$0.97 | -$1.02 | -$1.22 | -$1.42 |
Ocular Therapeutix Quarterly Results
| 2025 Q3 | 2025 Q4 | 2026 Q1 | 2026 Q2 | |
|---|---|---|---|---|
| Revenue | $14.5M | $13.2M | $10.8M | $13.5M |
| Net Income | -$69.4M | -$64.7M | -$88.6M | -$78.8M |
| Diluted EPS | -$0.38 | -$0.35 | -$0.40 | -$0.35 |
Ocular Therapeutix Balance Sheet
| FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | |
|---|---|---|---|---|---|---|
| Cash & Equivalents | $228.1M | $164.2M | $102.3M | $195.8M | $392.1M | $737.1M |
| Current Assets | $246.2M | $191.3M | $129.6M | $232.2M | $441.0M | $782.1M |
| Total Assets | $261.9M | $204.9M | $149.3M | $252.1M | $457.9M | $808.1M |
| Current Liabilities | $26.7M | $26.3M | $31.4M | $34.9M | $41.4M | $50.8M |
| Total Long-Term Debt | $49.5M | $51.4M | $54.0M | $65.8M | $68.5M | $71.3M |
| Total Liabilities | $185.8M | $116.9M | $113.9M | $160.9M | $142.6M | $153.7M |
| Shareholders' Equity | $76.1M | $88.0M | $35.4M | $91.1M | $315.3M | $654.3M |
Ocular Therapeutix Cash Flow Statement
| FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | |
|---|---|---|---|---|---|---|
| Cash From Operations | -$53.6M | -$65.5M | -$59.6M | -$70.2M | -$134.7M | -$204.9M |
| Cash From Investing | -$841,000 | -$1.2M | -$3.7M | -$6.1M | -$1.3M | -$11.9M |
| Cash From Financing | $228.0M | $2.9M | $1.5M | $169.8M | $332.1M | $561.7M |
| Free Cash Flow | -$54.4M | -$66.7M | -$63.3M | -$76.3M | -$136.0M | -$216.9M |
Figures from Ocular Therapeutix's 10-K and 10-Q filings with the SEC, as of 2026-10-14. Fiscal years follow the company's own reporting calendar. EPS and share counts are adjusted for later stock splits. See the full Ocular Therapeutix financials page for every line item.
Ocular Therapeutix Company Profile
| Ticker | OCUL |
|---|---|
| Exchange | Nasdaq |
| Industry | Pharmaceutical Preparations |
| Headquarters | Bedford, Massachusetts |
| Incorporated in | Delaware |
| Fiscal Year End | December 31 |
| SEC Filer Category | Large accelerated filer |
| SEC CIK | 0001393434 |
Frequently Asked Questions
What was Ocular Therapeutix's revenue in fiscal 2025?
Ocular Therapeutix (OCUL) reported revenue of $52.0M for fiscal 2025.
What is Ocular Therapeutix's annual revenue history?
Ocular Therapeutix's annual revenue by fiscal year: 2020: $17.4M; 2021: $43.5M; 2022: $51.5M; 2023: $58.4M; 2024: $63.7M; 2025: $52.0M.
What was Ocular Therapeutix's net income in fiscal 2025?
Ocular Therapeutix reported net income of -$265.9M for fiscal 2025.
What was Ocular Therapeutix's earnings per share (EPS) in fiscal 2025?
Ocular Therapeutix's diluted EPS was -$1.42 for fiscal 2025 (adjusted for any later stock splits).
How much free cash flow did Ocular Therapeutix generate in fiscal 2025?
Ocular Therapeutix generated -$216.9M of free cash flow in fiscal 2025.
What was Ocular Therapeutix's revenue last quarter?
In its most recent reported quarter (2026 Q2), Ocular Therapeutix reported revenue of $13.5M.
How much debt does Ocular Therapeutix have?
Ocular Therapeutix reported $71.3M of long-term debt, including the current portion, at the end of fiscal 2025.
How many shares of Ocular Therapeutix are outstanding?
Ocular Therapeutix reported a weighted average of 225.0 million basic shares outstanding in 2026 Q2.
What is Ocular Therapeutix's market cap?
Based on its latest closing price, Ocular Therapeutix (OCUL) has a market capitalization of about $1.63B.
When does Ocular Therapeutix's fiscal year end?
Ocular Therapeutix's fiscal year end, as registered with the SEC, is December 31.
Where is Ocular Therapeutix headquartered?
Ocular Therapeutix lists its business address in Bedford, Massachusetts in its SEC filings.